NCT05552495View on ClinicalTrials.gov

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

November 27, 2022

Study Completion Date

December 12, 2022

Conditions
Hypertension and Dyslipidemia
Interventions
DRUG

CKD-386(4) F1

1 Tablet

DRUG

CKD-386(4) F2

1 Tablet

DRUG

D013, D326, D337

D013 1 Tablet, D326 1Tablet, D337 1 Tablet

Trial Locations (1)

Unknown

H+ Yangji Hospita, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05552495 - Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter